Total Payments
$13,821
2024 Payments
$1,611
Companies
34
Transactions
192
Medicare Patients
10,256
Medicare Billing
$986,892
Payment Breakdown by Category
Research$8,262 (59.8%)
Food & Beverage$5,399 (39.1%)
Education$159.94 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8,262 | 1 | 59.8% |
| Food and Beverage | $5,399 | 189 | 39.1% |
| Education | $159.94 | 2 | 1.2% |
Payments by Type
Research
$8,262
1 transactions
General
$5,559
191 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $8,262 | 1 | $0 (2023) |
| GENZYME CORPORATION | $1,019 | 29 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $834.78 | 27 | $0 (2024) |
| Amgen Inc. | $573.52 | 7 | $0 (2024) |
| Incyte Corporation | $539.28 | 29 | $0 (2024) |
| PFIZER INC. | $446.56 | 29 | $0 (2024) |
| MERZ NORTH AMERICA, INC. | $378.89 | 1 | $0 (2021) |
| ABBVIE INC. | $295.12 | 5 | $0 (2024) |
| LEO Pharma Inc. | $222.40 | 9 | $0 (2024) |
| Dermavant Sciences, Inc. | $152.40 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,611 | 49 | Amgen Inc. ($298.60) |
| 2023 | $9,646 | 50 | Eli Lilly and Company ($8,262) |
| 2022 | $843.19 | 35 | GENZYME CORPORATION ($230.68) |
| 2021 | $790.28 | 20 | MERZ NORTH AMERICA, INC. ($378.89) |
| 2020 | $159.91 | 7 | Janssen Biotech, Inc. ($48.86) |
| 2019 | $388.74 | 9 | Amgen Inc. ($231.52) |
| 2018 | $166.79 | 9 | Novartis Pharmaceuticals Corporation ($63.19) |
| 2017 | $215.50 | 13 | Galderma Laboratories, L.P. ($53.13) |
All Payment Transactions
192 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $31.23 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/25/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $21.56 | General |
| Category: DERMATOLOGY | ||||||
| 11/20/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $22.05 | General |
| Category: Inflammation | ||||||
| 11/14/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $19.22 | General |
| Category: DERMATOLOGY | ||||||
| 11/07/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $6.04 | General |
| Category: DERMATOLOGY | ||||||
| 10/28/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $46.75 | General |
| Category: Immunology | ||||||
| 10/23/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $29.68 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/15/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $6.69 | General |
| Category: DERMATOLOGY | ||||||
| 09/19/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: DERMATOLOGY | ||||||
| 09/18/2024 | PFIZER INC. | CIBINQO (Drug), LITFULO | Food and Beverage | In-kind items and services | $16.14 | General |
| Category: Inflammation & Immunology | ||||||
| 09/03/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $4.75 | General |
| Category: DERMATOLOGY | ||||||
| 08/30/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $37.25 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/27/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $32.26 | General |
| Category: Immunology | ||||||
| 08/08/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: DERMATOLOGY | ||||||
| 08/06/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $101.27 | General |
| Category: IMMUNOLOGY | ||||||
| 07/29/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $35.49 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 07/18/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $18.51 | General |
| Category: DERMATOLOGY | ||||||
| 07/18/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $1.15 | General |
| Category: DERMATOLOGY | ||||||
| 07/17/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $25.59 | General |
| Category: DERMATOLOGY | ||||||
| 06/17/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $37.44 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/23/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $6.70 | General |
| Category: DERMATOLOGY | ||||||
| 05/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $27.61 | General |
| Category: IMMUNOLOGY | ||||||
| 05/14/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $21.93 | General |
| Category: DERMATOLOGY | ||||||
| 05/13/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $35.13 | General |
| Category: Immunology | ||||||
| 05/06/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: DERMATOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED SINGLE-ARM PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB | Eli Lilly and Company | $8,262 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 2,953 | 3,964 | $526,620 | $293,611 |
| 2022 | 21 | 2,755 | 3,630 | $477,380 | $266,256 |
| 2021 | 25 | 2,618 | 3,507 | $457,365 | $262,114 |
| 2020 | 19 | 1,930 | 2,532 | $316,960 | $164,911 |
Total Patients
10,256
Total Services
13,633
Medicare Billing
$986,892
Procedure Codes
91
All Medicare Procedures & Services
91 procedure records from CMS Medicare Utilization — Page 2 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 674 | 1,135 | $139,955 | $85,386 | 61.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 623 | 623 | $89,030 | $55,352 | 62.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 369 | 416 | $63,540 | $37,383 | 58.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 315 | 432 | $40,380 | $18,987 | 47.0% |
| 11106 | Incision biopsy, first skin growth | Office | 2022 | 81 | 86 | $18,330 | $12,000 | 65.5% |
| 11642 | Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | Office | 2022 | 37 | 41 | $14,810 | $9,463 | 63.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 129 | 169 | $25,770 | $9,258 | 35.9% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 108 | 152 | $14,045 | $7,089 | 50.5% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2022 | 133 | 176 | $23,395 | $5,685 | 24.3% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2022 | 23 | 28 | $8,725 | $5,606 | 64.3% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 46 | 49 | $7,955 | $4,926 | 61.9% |
| 11622 | Removal of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | Office | 2022 | 16 | 16 | $5,055 | $3,020 | 59.7% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 24 | 25 | $3,790 | $2,100 | 55.4% |
| 11641 | Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | Office | 2022 | 11 | 12 | $3,750 | $1,941 | 51.8% |
| 11104 | Punch biopsy, first skin growth | Office | 2022 | 15 | 15 | $2,755 | $1,771 | 64.3% |
| 11901 | Injection into skin growth, more than 7 growths | Office | 2022 | 15 | 25 | $2,425 | $1,561 | 64.4% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Office | 2022 | 17 | 17 | $2,575 | $1,432 | 55.6% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 17 | 17 | $1,930 | $959.05 | 49.7% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 56 | 148 | $4,770 | $899.61 | 18.9% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2022 | 17 | 18 | $1,560 | $873.00 | 56.0% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 11 | 12 | $975.00 | $389.46 | 39.9% |
| 88304 | Pathology examination of tissue using a microscope, moderately low complexity | Office | 2022 | 18 | 18 | $1,860 | $174.40 | 9.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 586 | 1,002 | $123,480 | $78,110 | 63.3% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 497 | 497 | $71,130 | $45,587 | 64.1% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 336 | 385 | $58,910 | $36,047 | 61.2% |
About Dr. Sid Danesh, M.D
Dr. Sid Danesh, M.D is a Dermatology healthcare provider based in San Gabriel, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1063447134.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sid Danesh, M.D has received a total of $13,821 in payments from pharmaceutical and medical device companies, with $1,611 received in 2024. These payments were reported across 192 transactions from 34 companies. The most common payment nature is "" ($8,262).
As a Medicare-enrolled provider, Danesh has provided services to 10,256 Medicare beneficiaries, totaling 13,633 services with total Medicare billing of $986,892. Data is available for 4 years (2020–2023), covering 91 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location San Gabriel, CA
- Active Since 07/11/2006
- Last Updated 07/08/2007
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1063447134
Products in Payments
- TALTZ (Drug) $8,365
- DUPIXENT (Biological) $1,837
- OPZELURA (Drug) $444.29
- EUCRISA (Drug) $349.11
- Otezla (Drug) $298.60
- Enbrel (Biological) $274.92
- RINVOQ (Biological) $193.85
- VTAMA (Drug) $152.40
- COSENTYX (Biological) $140.74
- ADBRY (Biological) $131.83
- TREMFYA (Drug) $108.87
- SKYRIZI (Biological) $101.27
- CIBINQO (Drug) $97.45
- ENSTILAR (Drug) $90.57
- DAXXIFY (Drug) $63.51
- Mupirocin Cream (Drug) $56.00
- REMICADE (Biological) $48.86
- CELLEX (Device) $40.10
- Sotyktu (Drug) $35.00
- DORYX (Drug) $31.93
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.